17th International Conference on Pathology & Cancer Epidemiology | Visit: https://pathology.euroscicon.com/

 Welcome to the 
17^th International Conference on Pathology & Cancer Epidemiology

Prognostic and predictive clinicopathologic factors of squamous anal canal cancer in HIV-positive and HIV-negative patients: Does HAART influence outcomes?

Pappou EP, et al. - Researchers aimed at delineating outcomes of anal squamous cell carcinoma (SCC) treatment in HIV-positive and human immunodeficiency virus (HIV)-negative patients. They observed that among patients with anal SCC, HIV infection was not associated with a significantly higher relapse rate or worse 5-year overall survival. A higher rate of relapse was evident in association with highly active antiretroviral therapy (HAART) in HIV-positive patients. Regardless of HIV status, AJCC staging predicted survival in both relapsed and non-relapsed patients.

Methods

•           Researchers performed a retrospective single-institution analysis on all patients with anal SCC treated at the JohnsHopkins Hospital between 1991 and 2010.

•           Five-year overall survival (5-year OS), median survival, and relapse rates were the primary outcome measures.

Results

•           Ninety-three patients with anal SCC were identified (mean age was 54 years; 37.6% were male, and 21.5% were HIV-positive).

•           Patients were followed-up for a median period of 28 months.

•           In 16.1% of patients, relapse occurred; median time was 20 months.

•           With HIV-positive vs negative patients, relapse rates were slightly higher (30.0 vs 12.3%), however, the difference did not reach statistical significance (p=0.06).

•           Patients who relapsed were more likely to be on HAART than those who did not relapse (83.3 vs 14.3%, p=0.007) among HIV-positive patients.

•           For the total group of patients, 5-year OS was 58.9%; no significant difference was evident between those who relapsed vs those who did not (76.2 vs 54.5%, p=0.20).

•           HIV-positive and negative patients showed no survival difference.

•           In all patients, survival was associated with AJCC stage.
For more details visit: https://pathology.euroscicon.com/

Pathology Conferences 2018 | October 08-09, 2018 | Edinburgh, Scotland | https://pathology.euroscicon.com/

Pathology & Cancer Epidemiology

Course Objectives

During the course, the participants will review a total of 200 cases of benign and malignant cutaneous tumors including 50 cases each of melanocytic, vascular, adnexal and lymphoproliferative neoplasms, respectively. Several common diagnostic problems concerning variants of melanoma and melanocytic nevi, high- and low-grade cutaneous vascular tumors and their simulators, cutaneous follicular, apocrine, eccrine and sebaceous neoplasms and cutaneous lymphomas and pseudolymphomas are included. On each day, at least 10 cases of each diagnostic group will be extensively discussed by an interactive approach. Particular attention will be paid to the diagnostic criteria with systematic analysis of differential diagnoses, as well as value and limitations of immunohistochemistry and molecular genetic tools. A comprehensive review and update of relevant literature will be provided. The discussion of the most interesting cases will be integrated into a more general diagnostic approach to these problematic cutaneous neoplasms.

More details visit: https://pathology.euroscicon.com/ 

Participants

This intensive course is designed for practicing pathologists as well as pathologists in training. Attendance is limited to 1000 participants.

Location / Course FeeEdinburgh, Scotland

Registration / More Information
https://pathology.euroscicon.com/registration

E-mail us your questions about the conference. We will respond to your questions.
pathology@eurosciconconferences.com
pathology@eurosciconmeetings.com
Web: https://pathology.euroscicon.com/

CONNECT with Global Speakers from all over Europe, USA, Asia & Middle East at International Pathology Conferences, Global Pathology Meetings

17th International Conference on

Pathology & Cancer Epidemiology

Theme: Pathology: Current trends, Advancements and Emerging Challenges

WHO SHOULD ATTEND ?

The Pathology Meeting 2018, Edinburgh, Scotland offers a platform for the Pathologists and experts both from Industry and Academia working in various sub domains of Pathology ranging from classical pathology to the advanced technologies and image analysis in Pathology including Pathological Diagnosis.

Professionals from Pathological Laboratories, Hospitals, and Academics:

Directors, Deans, Research Professionals, Laboratory heads, Lab managers, Lab technicians, Laboratory Professionals, Medical/ Biomedical scientists, Professors, Associate Professors, Assistant Professors, Research Practicing pathologist, Research Fellows, Medical students, Nurses, Residents, working in the arena of Pathology and its allied fields, but not limited to:

• Cytopathology and Histopathology
• Laboratory Medicine
• Gastroenterology
• Hematology
• Oncology
• Infection Control
• Surgical Pathology
• Clinical Pathology
• Dermatopathology
• Nephropathology
• Neuropathology
• Autopsy Pathology etc.

Industry partners and professionals, vendors in the arena of :

• Pathology
• Diagnostic Devices
• Imaging Products
• Pathology Lab Equipment manufacturers
• Commercial Diagnostics laboratories
• Clinical Research Organizations (CRO)
• Lab reagents, Assays and Kits suppliers
• Pathology service providers etc.

Leading companies with Clinical laboratory/ Pathology Services

• Alere
• Bio-Reference Laboratories
• DaVita Healthcare Partners
• Genomic Health
• Laboratory Corporation of America
• Myriad Genetics
• NeoGenomics
• Quest Diagnostics
• Siemens Healthineers
• Sonic Healthcare Limited
• Spectra Laboratories
• SYNLAB International 

Top companies associated with Pathology Products:

• Roche (Ventana/ BioImageneLeica)
• Hologic
• Qiagen
• Sakura
• BD
• Dako
• ThermoFisher
• Abbott
• Olympus

WHY ATTEND PATHOLOGY 2018

This Pathology Conference 2018 Provides a platform to learn about new upcoming technologies, future and current developments and lines of research determining the future of Pathology. Experts will discuss the pros and cons of all the developments and how the upcoming technologies or procedures will change the face of Pathology and Pathologists. Also, it is a platform, where everyone can share their ideas and interact with global experts to expand their knowledge in the arena of Pathology and to build new contacts creating collaborative research opportunities in the sector of Pathology and related disciplines.

Here is the quick insights of the upcoming Pathology Conference 2018 at Edinburgh, Scotland. 

• Meet the pathologists from 20+ countries around the globe
• Earn up to 21 CME/ CPD credits
• Meet your peers and evaluate your research in front of experts
• World-class platform to exhibit your products and services
• Special Workshop/ Symposiums, B2B and interactive sessions with industry Sponsors and Exhibitors
• More than 25 presentations from Industry and Academia leaders
• One- on -one interaction, B2B, and B2A etc.
• Well organizing program with 5+ hours of networking sessions
• Interactive panel discussions and Q&A sessions
• Lively Exhibition area filled with the leading industry solution providers

To download the brochure follow the link: Pathology Conferences

Please let me know if you will be able to attend.

Awaiting your early response.

EuroSciCon Ltd 40 Bloomsbury Way Lower Ground Floor London, United Kingdom WC1A 2SE E: pathology@eurosciconconferences.com